CCI rules in favour of Biocon in case against Roche over breast cancer drug

Biocon and Mylan started marketing biosimilars of Roche's Trastuzumab drug in 2014

The Competition Commission of India (CCI) has given directions for carrying out a detailed investigation to ascertain if Roche used its dominant position to maintain its monopoly over the breast cancer drug Trastuzumab.  

The order comes as a response to a joint complaint filed by the Mylan and Biocon in 2016 alleging that the Roche Group indulged in "abusive conduct".

"The Commission is of the considered view that, prima facie, the contravention with regard to Section 4(2)(c) of the Act is made out against Roche Group, which warrants a detailed investigation into the matter. The DG is, thus,